{
  "docId": "019de072-8046-72ee-8797-71c9ff7422eb",
  "docSlug": "98d74c454dfdfefd8fb9993ff5213b70",
  "documentTitle": "Hillevax | IPO Presentation Deck | 24 slides",
  "authorId": "hillevax",
  "authorName": "Hillevax",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 13,
  "pageCount": 24,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 18,
  "notes": "The table provides a comprehensive overview of the clinical program's scope and participant demographics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-8046-72ee-8797-71c9ff7422eb/13",
  "deckHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb",
  "deckJsonHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb.json",
  "deckAnchorHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1. Intranasal formulation of vaccine, not included in HIL-214 safety and immunogenicity subject numbers\nR: randomized. DB: double-blind. OL: open label. Pbo: placebo-controlled",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7045f727-99df-40d3-9731-5f237f4093f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "table",
      "text": "Trial No. Phase Design Study Population HIL-214 safety, n HIL-214 immuno, n",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46200da0-0cd2-487a-9cb1-bbe2d2b8f74b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Large clinical program demonstrates immunogenicity, efficacy, and safety/tolerability",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43b2bc69-4b8d-4df7-afec-064ccded03d3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 13,
      "beatId": "203d2e43-a365-49ec-802a-f481a270533f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 13-16 present clinical data supporting HIL-214's efficacy and safety",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}